28271030|t|High-fidelity Glucagon-CreER mouse line generated by CRISPR-Cas9 assisted gene targeting
28271030|a|α-cells are the second most prominent cell type in pancreatic islets and are responsible for producing glucagon to increase plasma glucose levels in times of fasting. α-cell dysfunction and inappropriate glucagon secretion occur in both type 1 and type 2 diabetes. Thus, there is growing interest in studying both normal function and pathophysiology of α-cells. However, tools to target gene ablation or activation specifically of α-cells have been limited, compared to those available for β-cells. Previous Glucagon-Cre and Glucagon-CreER transgenic mouse lines have suffered from transgene silencing, and the only available Glucagon-CreER "knock-in" mouse line results in glucagon haploinsufficiency, which can confound the interpretation of gene deletion analyses. Therefore, we sought to develop a Glucagon-CreER(T2) mouse line that would maintain normal glucagon expression and would be less susceptible to transgene silencing. We utilized CRISPR-Cas9 technology to insert an IRES-CreER(T2) sequence into the 3' UTR of the Glucagon (Gcg) locus in mouse embryonic stem cells (ESCs). Targeted ESC clones were then injected into mouse blastocysts to obtain Gcg-CreER(T2) mice. Recombination efficiency in GCG (+) pancreatic α-cells and glucagon-like peptide 1 positive (GLP1(+)) enteroendocrine L-cells was measured in Gcg-CreER(T2); Rosa26-LSL-YFP mice injected with tamoxifen during fetal development and adulthood. Tamoxifen injection of Gcg-CreER(T2); Rosa26-LSL-YFP mice induced high recombination efficiency of the Rosa26-LSL-YFP locus in perinatal and adult α-cells (88% and 95%, respectively), as well as in first-wave fetal α-cells (36%) and adult enteroendocrine L-cells (33%). Mice homozygous for the Gcg-CreER(T2) allele were phenotypically normal. We successfully derived a Gcg-CreER(T2) mouse line that expresses CreER(T2) in pancreatic α-cells and enteroendocrine L-cells without disrupting preproglucagon gene expression. These mice will be a useful tool for performing temporally controlled genetic manipulation specifically in these cell types.
28271030	14	39	Glucagon-CreER mouse line	T017	UMLS:C1513528
28271030	74	88	gene targeting	T062	UMLS:C0242613
28271030	89	96	α-cells	T017	UMLS:C0030280
28271030	127	136	cell type	T170	UMLS:C0449475
28271030	140	157	pancreatic islets	T017	UMLS:C0022131
28271030	192	200	glucagon	T103	UMLS:C0017687
28271030	213	234	plasma glucose levels	T033	UMLS:C0455280
28271030	247	254	fasting	T033	UMLS:C0015663
28271030	256	262	α-cell	T017	UMLS:C0030280
28271030	293	301	glucagon	T103	UMLS:C0017687
28271030	302	311	secretion	T038	UMLS:C0036536
28271030	326	332	type 1	T038	UMLS:C0011854
28271030	337	352	type 2 diabetes	T038	UMLS:C0011860
28271030	442	449	α-cells	T017	UMLS:C0030280
28271030	476	489	gene ablation	T062	UMLS:C1513384
28271030	493	503	activation	T038	UMLS:C0017255
28271030	520	527	α-cells	T017	UMLS:C0030280
28271030	579	586	β-cells	T017	UMLS:C0030281
28271030	597	609	Glucagon-Cre	T017	UMLS:C1513528
28271030	614	651	Glucagon-CreER transgenic mouse lines	T017	UMLS:C1513528
28271030	671	680	transgene	T017	UMLS:C0282641
28271030	681	690	silencing	T038	UMLS:C0598496
28271030	715	751	Glucagon-CreER "knock-in" mouse line	T017	UMLS:C1513528
28271030	763	771	glucagon	T103	UMLS:C0017687
28271030	772	790	haploinsufficiency	T038	UMLS:C2936267
28271030	833	855	gene deletion analyses	T058	UMLS:C1294202
28271030	891	920	Glucagon-CreER(T2) mouse line	T017	UMLS:C1513528
28271030	948	956	glucagon	T017	UMLS:C1333664
28271030	957	967	expression	T038	UMLS:C1171362
28271030	1001	1010	transgene	T017	UMLS:C0282641
28271030	1011	1020	silencing	T038	UMLS:C0598496
28271030	1070	1093	IRES-CreER(T2) sequence	T082	UMLS:C1512886
28271030	1103	1109	3' UTR	T082	UMLS:C0600600
28271030	1117	1125	Glucagon	T017	UMLS:C1333664
28271030	1127	1130	Gcg	T017	UMLS:C1333664
28271030	1132	1137	locus	T017	UMLS:C0678933
28271030	1141	1167	mouse embryonic stem cells	T017	UMLS:C4042879
28271030	1169	1173	ESCs	T017	UMLS:C4042879
28271030	1185	1188	ESC	T017	UMLS:C4042879
28271030	1189	1195	clones	T017	UMLS:C0009013
28271030	1220	1225	mouse	T204	UMLS:C0025929
28271030	1226	1237	blastocysts	T017	UMLS:C1281743
28271030	1248	1266	Gcg-CreER(T2) mice	T204	UMLS:C0025936
28271030	1268	1281	Recombination	T038	UMLS:C0034865
28271030	1296	1299	GCG	T103	UMLS:C0017687
28271030	1304	1322	pancreatic α-cells	T017	UMLS:C0030280
28271030	1327	1359	glucagon-like peptide 1 positive	T103	UMLS:C0061355
28271030	1361	1368	GLP1(+)	T103	UMLS:C0061355
28271030	1370	1393	enteroendocrine L-cells	T017	UMLS:C2333553
28271030	1410	1423	Gcg-CreER(T2)	T204	UMLS:C0025936
28271030	1425	1444	Rosa26-LSL-YFP mice	T204	UMLS:C0025936
28271030	1445	1453	injected	T058	UMLS:C0021485
28271030	1459	1468	tamoxifen	T103	UMLS:C0039286
28271030	1476	1493	fetal development	T038	UMLS:C0015928
28271030	1509	1518	Tamoxifen	T103	UMLS:C0039286
28271030	1519	1528	injection	T058	UMLS:C0021485
28271030	1532	1545	Gcg-CreER(T2)	T204	UMLS:C0025936
28271030	1547	1566	Rosa26-LSL-YFP mice	T204	UMLS:C0025936
28271030	1580	1593	recombination	T038	UMLS:C0034865
28271030	1612	1632	Rosa26-LSL-YFP locus	T017	UMLS:C0678933
28271030	1656	1663	α-cells	T017	UMLS:C0030280
28271030	1724	1731	α-cells	T017	UMLS:C0030280
28271030	1748	1771	enteroendocrine L-cells	T017	UMLS:C2333553
28271030	1779	1783	Mice	T204	UMLS:C0025929
28271030	1803	1816	Gcg-CreER(T2)	T017	UMLS:C0017337
28271030	1817	1823	allele	T017	UMLS:C0002085
28271030	1878	1902	Gcg-CreER(T2) mouse line	T017	UMLS:C1513528
28271030	1908	1917	expresses	T038	UMLS:C0017262
28271030	1918	1927	CreER(T2)	T017	UMLS:C0017337
28271030	1931	1949	pancreatic α-cells	T017	UMLS:C0030280
28271030	1954	1977	enteroendocrine L-cells	T017	UMLS:C2333553
28271030	1997	2011	preproglucagon	T017	UMLS:C1333664
28271030	2012	2027	gene expression	T038	UMLS:C0017262
28271030	2035	2039	mice	T204	UMLS:C0025929
28271030	2142	2152	cell types	T170	UMLS:C0449475